BioSpace News Archive

Study will measure immune responses to matched and drifted virus strains in older adults, a population that is most vulnerable to mortality from flu

GC Aesthetics, Inc., a privately-held medical technology company providing aesthetic solutions for global healthcare markets, is pleased to announce the launch of its next generation of breast implants, PERLE™.

Celularity to utilize MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance its off-the-shelf placental-derived allogeneic cellular therapies to treat hematological malignancies, solid tumors, and infectious and degenerative diseases

Latest funding round will support customer expansion at global scale, as well as significant investment in product and engineering

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, announced that the company will participate in the 2021 Jefferies Healthcare Conference being held virtually from June 1-4, 2021.

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced that Dr. David R. Parkinson, Chief Executive Officer of ESSA, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference.

Boston Scientific Corporation announced it has completed CE Mark for the EXALT™ Model B Single-Use Bronchoscope, a single-use device designed for bedside procedures in the intensive care unit, operating room and bronchoscopy suite.

Epizyme, a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that Robert Bazemore, President and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:30 p.m. ET.

Xilio to evaluate XTX101, a tumor selective anti-CTLA-4 monoclonal antibody, in combination with KEYTRUDA® (pembrolizumab) as a treatment for patients with solid tumors

Newly formed publicly traded company NRx Pharmaceuticals, Inc. (NRx) to be traded under the ticker symbol “NRXP” on the Nasdaq Global Market